

Fabien Calvo, 57, MD PhD, Deputy Director, has been in charge of the Research Programmes at the National Cancer Institute since April 2007. Fabien CALVO is the director of the Multi-Institutions Institute, thematic "Cancer" Previously resident and senior registrar of Paris Hospitals, research associate of the National Cancer Institute in Bethesda (NIH / NCI / DCT, USA), he specialised in oncology and haematology. He is also a professor of pharmacology at the Denis Diderot Medical University in Paris.

He has been the director of the Saint-Louis Hospital CIC (clinical investigation center) and he was the director of INSERM unit 716 on the identification of new molecular targets for the treatment of cancer from 1995 to 2008. He is a member of the post-graduate school "oncogenesis fundamental basis". He also headed the clinical research programmes in cancer in the Paris area. He has published more than 200 original and review articles.

His spheres of activity and interest are the biology of metastatic processes, especially proteases, translational research, preclinical pharmacology and early clinical trials in haematology and oncology.

He also worked as a coordinator of the cancer mission for the Director of the Research and Innovation department, Ministry of Research and Higher Education in 2006 and 2007.

5 major recent publications :

Kerob D, Pedeutour F, Leboeuf C, Verola O, de Kerviler E, Servant JM, Sarandi F, Bousquet G, Madelaine-Chambrin I, Pruvost C, Calvo F, Janin A, Lebbe C. Value of cytogenetic analysis in the treatment of dermatofibrosarcoma protuberans.

J Clin Oncol. 2008 Apr 1;26(10):1757-9.

Scamuffa N, Siegfried G, Bontemps Y, Ma L, Basak A, Cherel G, Calvo F, Seidah NG, Khatib AM. Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells.

J Clin Invest. 2008 Jan;118(1):352-63.

Lapierre M, Siegfried G, Scamuffa N, Bontemps Y, Calvo F, Seidah NG, Khatib AM. Opposing function of the proprotein convertases furin and PACE4 on breast cancer cells' malignant phenotypes: role of tissue inhibitors of metalloproteinase-1.

Cancer Res. 2007 Oct 1;67(19):9030-4.

Bergeron A, Réa D, Levy V, Picard C, Meignin V, Tamburini J, Bruzzoni-Giovanelli H, Calvo F, Tazi A, Rousselot P. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.

Am J Respir Crit Care Med. 2007 Oct 15;176(8):814-8.

Quemener C, Gabison EE, Naïmi B, Lescaille G, Bougatef F, Podgorniak MP, Labarchède G, Lebbé C, Calvo F, Menashi S, Mourah S. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.

Cancer Res. 2007 Jan 1;67(1):9-15.